457 related articles for article (PubMed ID: 20707757)
1. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
2. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
Curtit E; Thiery-Vuillemin A; Nguyen T; Heyd B; Pivot X; Di Martino V; Borg C
J Clin Oncol; 2011 Apr; 29(12):e330-2. PubMed ID: 21263091
[No Abstract] [Full Text] [Related]
3. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
4. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
5. Novel molecular therapies in hepatocellular carcinoma.
Faivre S; Bouattour M; Raymond E
Liver Int; 2011 Jan; 31 Suppl 1():151-60. PubMed ID: 21205154
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
Kim HY; Park JW
Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
[TBL] [Abstract][Full Text] [Related]
7. Latest developments in targeted therapy for hepatocellular carcinoma.
Montella L; Addeo R; Caraglia M; Del Prete S
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1635-46. PubMed ID: 20942634
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
9. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Zhu AX
Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
[TBL] [Abstract][Full Text] [Related]
10. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
11. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
12. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
[TBL] [Abstract][Full Text] [Related]
13. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
Saidi RF; Shah SA; Rawson AP; Grossman S; Piperdi B; Bozorgzadeh A
Transplant Proc; 2010 Dec; 42(10):4582-4. PubMed ID: 21168742
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
[TBL] [Abstract][Full Text] [Related]
15. Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
Frenette CT; Frederick RT; Gish RG
J Clin Gastroenterol; 2011 Sep; 45(8):733-7. PubMed ID: 20930642
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
O'Neil BH; Venook AP
Oncologist; 2007 Dec; 12(12):1425-32. PubMed ID: 18165619
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
18. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
Rimassa L; Santoro A
Dig Liver Dis; 2010 Jul; 42 Suppl 3():S273-80. PubMed ID: 20547314
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
Kuzuya T; Tsuchiya K; Izumi N
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944
[No Abstract] [Full Text] [Related]
20. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]